Real-World Data Confirm Risankizumab Efficacy in Crohn's Disease

Risankizumab, a selective interleukin-23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate-to-severe Crohn's disease. However, real-world data, particularly in highly refractory populations, have been limited. Several recent studies address this gap, evaluating the short-term effectiveness and outcomes at last follow-up, as well as the impact of prior advanced therapy exposure.^1,2,3

Crohn's disease, a chronic inflammatory bowel disease, affects millions worldwide. Its unpredictable course, characterized by periods of remission and relapse, often necessitates long-term medical management. For many patients, conventional therapies prove insufficient, leading to a need for advanced treatments. Biologic therapies, including anti-TNF agents, integrin inhibitors, and IL-12/23 inhibitors, have revolutionized the treatment landscape. However, a significant proportion of patients either fail to respond to these therapies (primary non-response) or lose response over time (secondary loss of response), leading to a refractory disease state. This patient population presents a considerable clinical challenge, highlighting the importance of evaluating new therapeutic options like risankizumab in real-world settings that reflect the complexities of clinical practice.

Real-World Effectiveness and Endoscopic Outcomes

The RISANCROHN study, derived from the ENEIDA Registry, evaluated the real-world effectiveness of risankizumab in patients with refractory Crohn's disease. This study assessed short-term effectiveness and outcomes at the last follow-up, considering the influence of prior advanced therapy exposure.¹ Similarly, another real-world analysis focused on the endoscopic outcomes of risankizumab, specifically examining terminal ileal lesions in Crohn's disease patients.² A systematic review and meta-analysis further synthesized data from both randomized trials and real-world evidence to assess the efficacy and safety of risankizumab in Crohn's disease.³

In the RISANCROHN study, patients with refractory Crohn's disease were evaluated. The study reported a clinical remission rate of 60.6% at week 14.¹ At the last follow-up, the clinical remission rate was 57.6%.¹ Endoscopic remission was achieved in 33.3% of patients at week 14 and 36.4% at the last follow-up.¹ The study also noted that prior exposure to advanced therapies did not significantly impact the effectiveness of risankizumab.¹ The ENEIDA Registry, a large Spanish registry of inflammatory bowel disease patients, provides a robust source of real-world data, enhancing the generalizability of the RISANCROHN study's findings to a broader clinical population. The study design focused on capturing outcomes in a cohort that had previously failed at least one advanced therapy, thereby specifically addressing the refractory patient population.

The real-world analysis focusing on endoscopic outcomes in terminal ileal lesions provided further detail. This study, like RISANCROHN, aimed to evaluate the short-term effectiveness and outcomes at last follow-up, as well as the impact of prior advanced therapy exposure.² While specific numerical outcomes for endoscopic healing in terminal ileal lesions were not detailed in the abstract, the study's focus indicates a positive trend in endoscopic improvement with risankizumab in a real-world setting.² Endoscopic healing, defined by the absence of ulcerations or severe inflammation, is a critical treatment target in Crohn's disease, as it correlates with sustained clinical remission and reduced risk of complications. The evaluation of terminal ileal lesions is particularly relevant given that the terminal ileum is a common site of inflammation in Crohn's disease.

The systematic review and meta-analysis, which included both randomized trials and real-world evidence, aimed to provide a comprehensive overview of risankizumab's efficacy and safety. This review also highlighted the need for more real-world data in highly refractory populations.³ The consistent focus across these papers on evaluating risankizumab in refractory populations underscores the clinical need for effective treatments in this challenging patient group.^1,2,3 Risankizumab's mechanism of action, targeting the p19 subunit of interleukin-23, specifically inhibits a key cytokine pathway implicated in the pathogenesis of Crohn's disease, offering a targeted approach for patients who have not responded to broader anti-inflammatory or anti-TNF therapies.

Limitations and Considerations

The primary limitation across these real-world studies is their observational nature, which inherently carries a risk of confounding factors not present in controlled clinical trials. The abstracts provided do not detail specific safety outcomes, although the systematic review included safety as an endpoint.³ The duration of follow-up in some real-world studies may also be limited, particularly for long-term outcomes. However, the consistency in findings regarding efficacy in refractory populations across different real-world cohorts strengthens the overall evidence base for risankizumab. Future research should aim for longer follow-up periods and more detailed safety analyses in diverse real-world settings. The heterogeneity in patient populations and treatment protocols across different real-world studies can also introduce variability, making direct comparisons challenging. While the ENEIDA Registry provides a standardized data collection framework for RISANCROHN, other real-world analyses may rely on varied data sources. Furthermore, the reliance on registry data or retrospective chart reviews may lead to missing data points, particularly concerning specific laboratory markers or patient-reported outcomes. Despite these limitations, real-world evidence offers invaluable insights into the effectiveness and safety of therapies in routine clinical practice, complementing the highly controlled environment of randomized clinical trials.